Of the 29 matched samples with concordant alterations in tumor tissue DNA and urine cfDNA, mutations were detected in the following driver gene mutations: EGFR (34%), TP53 (45%), RB1 (30%), and DNMT3A (7%). The gene discussed is DNMT3A; the disease is neoplasm.